HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease.

Abstract
Abeta peptide accumulation is thought to be the primary event in the pathogenesis of Alzheimer's disease (AD), with downstream neurotoxic effects including the hyperphosphorylation of tau protein. Glycogen synthase kinase-3 (GSK-3) is increasingly implicated as playing a pivotal role in this amyloid cascade. We have developed an adult-onset Drosophila model of AD, using an inducible gene expression system to express Arctic mutant Abeta42 specifically in adult neurons, to avoid developmental effects. Abeta42 accumulated with age in these flies and they displayed increased mortality together with progressive neuronal dysfunction, but in the apparent absence of neuronal loss. This fly model can thus be used to examine the role of events during adulthood and early AD aetiology. Expression of Abeta42 in adult neurons increased GSK-3 activity, and inhibition of GSK-3 (either genetically or pharmacologically by lithium treatment) rescued Abeta42 toxicity. Abeta42 pathogenesis was also reduced by removal of endogenous fly tau; but, within the limits of detection of available methods, tau phosphorylation did not appear to be altered in flies expressing Abeta42. The GSK-3-mediated effects on Abeta42 toxicity appear to be at least in part mediated by tau-independent mechanisms, because the protective effect of lithium alone was greater than that of the removal of tau alone. Finally, Abeta42 levels were reduced upon GSK-3 inhibition, pointing to a direct role of GSK-3 in the regulation of Abeta42 peptide level, in the absence of APP processing. Our study points to the need both to identify the mechanisms by which GSK-3 modulates Abeta42 levels in the fly and to determine if similar mechanisms are present in mammals, and it supports the potential therapeutic use of GSK-3 inhibitors in AD.
AuthorsOyinkan Sofola, Fiona Kerr, Iain Rogers, Richard Killick, Hrvoje Augustin, Carina Gandy, Marcus J Allen, John Hardy, Simon Lovestone, Linda Partridge
JournalPLoS genetics (PLoS Genet) Vol. 6 Issue 9 Pg. e1001087 (Sep 02 2010) ISSN: 1553-7404 [Electronic] United States
PMID20824130 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Amyloid beta-Protein Precursor
  • Drosophila Proteins
  • Mutant Proteins
  • Peptides
  • tau Proteins
  • Phosphoserine
  • Lithium
  • Sgg protein, Drosophila
  • Glycogen Synthase Kinase 3
Topics
  • Aging (drug effects, pathology)
  • Alzheimer Disease (enzymology, mortality, pathology, physiopathology)
  • Amyloid beta-Protein Precursor (metabolism, toxicity)
  • Animals
  • Disease Models, Animal
  • Drosophila Proteins (antagonists & inhibitors, metabolism)
  • Drosophila melanogaster (drug effects, enzymology)
  • Genes, Dominant (genetics)
  • Glycogen Synthase Kinase 3 (antagonists & inhibitors, metabolism)
  • Humans
  • Lithium (pharmacology)
  • Mutant Proteins (toxicity)
  • Nervous System (drug effects, metabolism, pathology)
  • Neurons (drug effects, enzymology, pathology)
  • Peptides (toxicity)
  • Phosphorylation (drug effects)
  • Phosphoserine (metabolism)
  • tau Proteins (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: